Novo Nordisk opens new modern insulin facility in Russia

10 April 2015

Danish diabetes care giant Novo Nordisk (NOV: N) today opened a new manufacturing facility in Russia for formulation and filling of modern insulin for the treatment of diabetes.

The production will cover both Penfill cartridges and FlexPen prefilled insulin injection pens for the Russian market. The new facility will be operating in accordance with current Good Manufacturing Practices (cGMP), and is located in Technopark Grabtsevo in the Kaluga region of Russia.

Ground-breaking on the new facility, which involved an investment of around $100 million, took place in 2012. Novo Nordisk has said previously that it plans to continue to increase local production of its products in Russia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK